# Lineage Cell Therapeutics, Inc. (LCTX)

> Lineage Cell Therapeutics, Inc. (LCTX) trades at $0.8385 (+2.78%) as of 7:30:02 PM EST on Nov 18, 2026, -13.79% over the past month. Market cap is $206.36M, with 19.3 days to cover in short interest.

Canonical: https://massive.com/quote/lctx
Data as of: 2026-11-19T00:30:02.374Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$0.8385** +0.02 (+2.78%)
At close · 15-minute delayed
NYSE American · usd

After hours: **$0.8350** -0.00 (-0.42%)
As of 7:30:02 PM EST on Nov 18, 2026 · After hours

## Stock performance

How Lineage Cell Therapeutics, Inc. (LCTX) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +2.78% |
| 1W | -24.46% |
| 1M | -13.79% |
| YTD | -49.79% |
| 1Y | -50.96% |
| 52-wk range | $0.77 – $1.99 |

From daily closes through Nov 18, 2026.

## Key statistics

Today's trading snapshot for LCTX: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $0.82 – $0.86 |
| Open | $0.82 |
| Prev close | $0.82 |
| Volume | 1.22M |
| Market cap | $206.36M |
| Shares out | 252.95M |

## Valuation and profitability ratios

Valuation and profitability ratios for Lineage Cell Therapeutics, Inc.: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | 118.32 |
| P/S | 19.14 |
| P/B | 3.09 |
| P/FCF | — |
| ROE | 2.6% |
| ROA | 1.8% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 17, 2026

## Insider trading

[Lineage Cell Therapeutics, Inc. (LCTX) insider trading](https://massive.com/quote/lctx/insider-trading.md): open-market Form 4 buys and sells by Lineage Cell Therapeutics, Inc. insiders over the last 12 months.

## 8-K filings

Material corporate events Lineage Cell Therapeutics, Inc. has disclosed to the SEC on Form 8-K.

- Nov 12, 2026 · Licensing agreement
  “Under the License Agreement, NeuroAirmid and Lineage ... received an exclusive license under specified patent rights relating to neural stem cell compositions and methods to treat neurodegenerative disorders, and a nonexclusive license to associated technology, to develop, manufacture and commercialize licensed products.”
- Jun 12, 2026 · Deal withdrawal
  “On June 9, 2026, following comments to the application received by the Company from CIRM, the Company elected to withdraw its application for the CIRM Grant. The withdrawal of the application does not impact the Company's current and planned development of OPC1 in the ongoing DOSED clinical study.”
- Mar 11, 2026 · Public offering
  “On March 11, 2026, Lineage Cell Therapeutics, Inc. (the "Company") filed with the U.S. Securities and Exchange Commission (the "SEC") a prospectus supplement dated March 11, 2026 relating to the offer and sale of the Company's common shares from time to time through or to B. Riley Securities, Inc. ("B. Riley"), pursuant to the sales agreement the Company entered into with B. Riley dated March 22, 2024. The Prospectus Supplement relates to the offer and sale of the Company's common shares under the Sales Agreement having an aggregate offering price of up to $60,000,000 (the "ATM Shares").”
- Nov 24, 2025 · Partnership or collaboration
  “In December 2021, Lineage Cell Therapeutics, Inc. entered into a collaboration and license agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. (the 'Roche Agreement') under which our lead cell therapy program known as OpRegen® (also known as RG6501) is being developed for the treatment of ocular disorders, including geographic atrophy ('GA') secondary to age-related macular degeneration ('AMD').”
- Aug 26, 2025 · Strategic initiative
  “The main objective of the RCA is for the parties to complete a preclinical phase achieving readiness to potentially progress to human clinical trials under one or more separate clinical agreements, representing a material advancement of Lineage's auditory neuronal cell transplant program.”

## LCTX short interest

How heavily LCTX is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 19.3 |
| Short interest | 24.35M |
| Avg volume | 1.26M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## LCTX news

The latest news and headlines about Lineage Cell Therapeutics, Inc. (LCTX).

- [Lineage Cell (LCTX) Reports Q3 Loss, Misses Revenue Estimates](https://www.zacks.com/stock/news/3029030/lineage-cell-lctx-reports-q3-loss-misses-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3029030) · Zacks Investment Research · Nov 12, 2026 · negative sentiment
- [Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets](https://www.benzinga.com/pressreleases/26/05/n52690815/cell-based-therapies-poised-to-disrupt-multi-billion-dollar-anti-aging-and-neurodegenerative-marke?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · May 20, 2026 · positive sentiment
- [Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells](https://www.benzinga.com/pressreleases/26/04/n51754139/biotechs-racing-to-translate-longevity-science-into-real-therapies-and-one-microcap-company-is-pro?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Apr 10, 2026 · positive sentiment
- [A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.](https://www.benzinga.com/pressreleases/26/03/n51325255/a-key-master-protein-that-declines-by-half-after-age-40-one-company-found-a-way-to-restore-it?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Mar 18, 2026 · positive sentiment
- [Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration](https://www.benzinga.com/pressreleases/26/01/n50242865/longevity-biotech-stocks-surge-as-27-trillion-healthcare-shift-favors-cell-restoration?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Jan 29, 2026 · positive sentiment

## About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

| Measure | Value |
| --- | --- |
| Exchange | NYSE American |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 77 |
| Listed | Mar 5, 1992 |

[Company website](https://www.lineagecell.com)

## FAQ

### What is the Lineage Cell Therapeutics, Inc. (LCTX) stock price today?

Lineage Cell Therapeutics, Inc. (LCTX) is trading at $0.8385 (+2.78% on the day) as of 7:30:02 PM EST on Nov 18, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Lineage Cell Therapeutics, Inc.?

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases.

### What is the short interest in LCTX?

As of Oct 30, 2026, LCTX has 24.35M shares short and 19.3 days to cover.

### What exchange is LCTX listed on?

Lineage Cell Therapeutics, Inc. (LCTX) trades on NYSE American in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

## Live data

Prices here are 15-minute delayed. For real-time LCTX quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=LCTX`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Lineage Cell Therapeutics, Inc. (LCTX) insider trading](https://massive.com/quote/lctx/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
